Background: It is unclear whether the overall effectiveness and safety of direct oral
anticoagulants (DOACs) are consistent in patients with nonvalvular atrial fibrillation (AF) and …

Objectives Concerns have arisen recently over the relationship between body mass index
(BMI) and outcomes in atrial fibrillation (AF) patients with direct oral anticoagulants (DOACs) …

Aims This study sought to determine the impact of weight and body mass index (BMI) on the
safety and efficacy of direct-acting oral anticoagulants (DOACs) compared with warfarin in …

Objectives This study sought to evaluate direct oral anticoagulant (DOAC) outcomes (vs.
warfarin) in patients with atrial fibrillation (AF) across body mass index (BMI) categories …

Despite evolving evidence, the use of direct oral anticoagulants (DOACs) in patients with
extremes of body weight remains controversial. This study aimed to measure the impact of …

Introduction Due to fixed dosing of direct oral anticoagulants (DOACs), uncertainty exists
about their efficacy in a population of obese/overweight patients. Patients and methods We …

Essentials• The association of body weight and patient‐important outcomes remains
unknown.• Phase III randomized controlled trials of direct oral anticoagulants (DOACs) were …

BACKGROUND: The efficacy and safety of non–vitamin-K antagonist oral anticoagulants
(NOACs) across the spectrum of body mass index (BMI) and body weight (BW) remain …

Background There is a paucity of evidence regarding the effects of non-vitamin K antagonist
oral anticoagulants (NOACs) in underweight patients with atrial fibrillation (AF). Objective …

Highlights•Direct oral anticoagulants did not increase stroke or systemic embolism event
rate.•Direct oral anticoagulants had lower major bleeding rate than warfarin.•Direct oral …